Streetbeat News

LIPO

Lipella Pharmaceuticals Inc.

https://www.lipella.com

Industry

Biotechnology

Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.

Open

3.30

Mkt cap

3.8M

Volume

235K

High

3.33

P/E Ratio

-0.73

52-wk high

12.00

Low

3.12

Div yield

N/A

52-wk low

2.21

Lipella Pharmaceuticals Inc. announced positive topline results from its Phase 2a clinical trial for LP-310, a treatment for Oral Lichen Planus. This development could enhance the company's prospects in the pharmaceutical market.

Portfolio Pulse from

February 11, 2025 | 11:00 am

Lipella Pharmaceuticals announced positive Phase 2a trial results for LP-310, a treatment for oral lichen planus, showing significant reductions in pain, ulceration, and inflammation. The trial will advance to a higher dose, with recruitment concluding in the first half of 2025. Lipella will present these findings at the BIO CEO & Investor Conference.

Portfolio Pulse from

February 11, 2025 | 11:00 am

Lipella Pharmaceuticals has received FDA approval for an Expanded Access Program for LP-310, a treatment for oral lichen planus. This approval allows more patients to access the therapy, potentially boosting the company's market presence.

Portfolio Pulse from

February 06, 2025 | 11:15 am

Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) has received FDA approval for an Expanded Access Program for its drug LP-310, aimed at treating Oral Lichen Planus. This development marks a significant step for the clinical-stage biotechnology company in addressing unmet medical needs.

Portfolio Pulse from

February 06, 2025 | 11:15 am

Spartan Capital Securities, LLC successfully completed two private placements for Lipella Pharmaceuticals Inc., raising $875,500 through Series B non-voting convertible preferred stock.

Portfolio Pulse from

January 10, 2025 | 6:45 pm

Spartan Capital Securities, LLC concluded 2024 with significant transactions in December, enhancing its status as a reliable investment banking partner for rapidly expanding companies in various sectors.

Portfolio Pulse from

December 31, 2024 | 5:15 pm

Spartan Capital Securities LLC successfully completed a $1.72 million private placement for Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), acting as the sole placement agent. Lipella raised funds through the sale of Series B non-voting convertible preferred stock.

Portfolio Pulse from

December 18, 2024 | 7:45 pm

Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) announced the publication of a peer-reviewed article in CUREUS, highlighting a potential non-steroid treatment for Oral Lichen Planus (OLP) with a focus on localized drug delivery.

Portfolio Pulse from

December 03, 2024 | 1:45 pm

Lipella Pharmaceuticals has completed the first cohort in its Phase 2a trial of LP-310 for treating Oral Lichen Planus and is advancing to the next dose group.

Portfolio Pulse from

November 21, 2024 | 10:45 am

Lipella Pharmaceuticals has completed the first cohort in its Phase 2a trial of LP-310 for Oral Lichen Planus, showing promising initial results. The trial will now advance to the next dose group.

Portfolio Pulse from

November 21, 2024 | 10:45 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.